



## CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum



Boris-Stephan Rauchmann<sup>a,b</sup>, Thomas Schneider-Axmann<sup>b</sup>, Panagiotis Alexopoulos<sup>c,d</sup>, Robert Perneczky<sup>b,e,f,g,\*</sup>, for the Alzheimer's Disease Neuroimaging Initiative<sup>1</sup>

<sup>a</sup> Department of Radiology, University Hospital, LMU Munich, Munich, Germany

<sup>b</sup> Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany

<sup>c</sup> Department of Psychiatry, University Hospital of Rion, University of Patras, Patras, Greece

<sup>d</sup> Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany

<sup>e</sup> German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany

<sup>f</sup> Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

<sup>g</sup> Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK

### ARTICLE INFO

#### Article history:

Received 31 July 2018

Received in revised form 28 September 2018

Accepted 17 October 2018

Available online 25 October 2018

#### Keywords:

Alzheimer's disease

Dementia

Mild cognitive impairment

Biomarker

Neuroinflammation

Neurodegeneration

Imaging

Prediction

### ABSTRACT

TREM2 was suggested to be an important regulator of microglia during neurodegeneration, but previous studies report conflicting results in relation to soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF) when using clinical criteria to classify Alzheimer's disease (AD). The present study explores sTREM2 CSF levels and their associations with other biomarkers and cognitive measures in a prospective AD cohort. Based on the available CSF biomarker information, 497 subjects were classified according to the 2018 National Institute on Aging–Alzheimer's Association research framework guidelines, which group biomarkers into those of amyloid- $\beta$  deposition, tau pathology, and neurodegeneration. CSF sTREM2 concentrations were associated with markers of neurodegeneration and fibrillar tau pathology, but not amyloidosis; sTREM2 concentrations were increased in total tau–positive versus –negative individuals; sTREM2 was not related to cognitive and other biomarker changes over time; and sTREM2 concentrations increased over time in total tau–positive versus –negative individuals with AD pathophysiology. The present study provides evidence in support of sTREM2 in CSF as a marker of neuroinflammation across the spectrum of early clinical AD. sTREM2 is linked to neuronal injury and may therefore offer complementary information relevant for diagnostic purposes and novel treatment approaches targeting the immune system in AD.

© 2018 Elsevier Inc. All rights reserved.

### 1. Introduction

Microglia activation and other innate immune responses seem to be associated with most neurodegenerative conditions, but the underlying mechanisms are still poorly understood. Single-nucleotide polymorphisms related to microglia function were shown to be linked to neurodegeneration. For example, single-

nucleotide polymorphisms in the Triggering receptor expressed on myeloid cells 2 (*TREM2*) gene have been associated with Alzheimer's disease (AD) and other neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, amyotrophic lateral sclerosis, and frontotemporal dementia (Borroni et al., 2014; Cady et al., 2014; Cuyvers et al., 2013, 2014; Guerreiro et al., 2013a,b; Jonsson et al., 2013; Rayaprolu et al., 2013; Walton et al., 2016).

TREM2 was suggested to be an important regulator of microglia during neurodegeneration (Kleinberger et al., 2017; Ulland et al., 2017). Functional imaging studies on mice using positron emission tomography (PET) showed that TREM2 plays a role in microglia activation during normal aging and is needed to maintain physiological cerebral energy metabolism (Kleinberger et al., 2017). The soluble form of TREM2 (sTREM2) is accessible as a biomarker in cerebrospinal fluid (CSF) because its ectodomain is shed by ADAM10 in a process similar to the intramembrane proteolysis of

\* Corresponding author at: Division of Mental Health of Older Adults, Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Nußbaumstr. 7, Munich 80336, Germany. Tel.: +49 89 4400-53439; fax: +49 89 4400-53413.

E-mail address: [robert.perneczky@med.lmu.de](mailto:robert.perneczky@med.lmu.de) (R. Perneczky).

<sup>1</sup> Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: [http://adni.loni.usc.edu/wp-content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf).

APP (Kleinberger et al., 2014). However, several previous studies report conflicting results with CSF sTREM2 concentrations shown to be increased (Heslegrave et al., 2016; Piccio et al., 2016; Suarez-Calvet et al., 2016b), decreased (Kleinberger et al., 2014), or normal in AD (Gispert et al., 2017), suggesting that sTREM2 levels vary with disease progression. Findings in autosomal dominant AD suggest that CSF sTREM2 increases several years before the expected symptom onset in mutation carriers, but after amyloid  $\beta$  (A $\beta$ ) deposition and neuronal injury have already occurred (Suarez-Calvet et al., 2016a). Moreover, previous work indicates that sTREM2 is associated with biomarkers of tau fibrillar pathology, neurodegeneration, and glial proteins in AD, but not with A $\beta$  pathophysiology (Gispert et al., 2016; Heslegrave et al., 2016; Piccio et al., 2016; Suarez-Calvet et al., 2016b). It was also reported in former National Football League players that cumulative exposure to repetitive head impact and microglial activation estimated by CSF sTREM2 were linked to higher CSF total tau (tTau) levels, but not to CSF A $\beta$  or phosphorylated tau (pTau) (Alosco et al., 2018); it was suggested that chronic microglial activation may subsequently lead to tau hyperphosphorylation associated with chronic traumatic encephalopathy (Cherry et al., 2016).

The available evidence suggests that sTREM2 levels increase in association with neuronal damage rather than with the appearance of A $\beta$  plaques per se and that sTREM2 may be linked to neurodegeneration in the absence of fibrillar tau pathology. It remains, however, to be clarified how sTREM2 is related to the core pathological changes along the AD continuum. Therefore, in the present study we used the biomarker-based classification system proposed in the recently published National Institute of Aging–Alzheimer's Association (NIA-AA) research framework (Jack et al., 2018). This approach allowed us to contrast groups of individuals with different biomarker profiles. We tested the main hypotheses that sTREM2 concentrations differ between the NIA-AA groups; and that cross-sectional and longitudinal associations between sTREM2 and other relevant AD markers are also related to the NIA-AA groups.

## 2. Methods

Data used in the preparation of this article were obtained from the AD Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)) on 16th March 2018. The ADNI was launched in 2003 as a public-private partnership, led by principal investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), PET, and additional biological markers and clinical and neuropsychological assessments can be combined to measure the progression of mild cognitive impairment (MCI) and early clinical AD. Participants were aged between 55 and 90 years (inclusive), considered cognitively normal (CN), MCI, or AD dementia—diagnosed individuals, and underwent serial evaluations of functional, biomedical, neuropsychological, and clinical status at various intervals.

### 2.1. Study population

AD could only be diagnosed in the dementia stage until recently different sets of criteria were presented with a stronger focus on biomarkers, including neuroimaging and CSF proteins. The guidelines proposed by the NIA-AA conceptualized AD as a progressive disorder including all possible stages from asymptomatic to severely impaired (Jack et al., 2011; McKhann, 2011), allowing AD to be diagnosed in the MCI stage if the presence of AD pathophysiology is supported by the typical biomarker findings (Giaccone et al., 2011). In the recently updated guidelines (i.e., the NIA-AA research framework (Jack et al., 2018)), AD is defined by its

pathological processes, which can be measured in vivo using biomarkers, and not by its clinical consequences. The relevant biomarker measures are grouped into those of A $\beta$  deposition (A), tau pathology (T), and neurodegeneration (N), which in the present study were assessed by decreased A $\beta$ 42, increased pTau181, and increased tTau in the CSF, respectively. CSF biomarker values were binarized into normal versus abnormal for the purposes of amyloid/tau/neurodegeneration (ATN) classification. References for the cutoff values used to define CSF biomarker abnormality are provided in the Section 2.2.

The present study used data collected at the baseline and over 48 months in 12-month increments from individuals participating in ADNI 1, ADNI 2, and ADNI GO, for whom complete CSF biomarker information was available (A $\beta$ 42, pTau181, and tTau). The study cohort included subjects with a baseline clinical classification of CN ( $n = 138$ ), MCI ( $n = 302$ ), or AD dementia ( $n = 57$ ). CN was defined as Mini-Mental-State Examination score between 25 and 30, inclusive; CDR score of 0; no evidence of depression; and no memory complaints. MCI was defined as Mini-Mental-State Examination score between 24 and 30, inclusive; CDR score of 0.5; report of memory complaints; and no significant functional impairment. All individuals with MCI also met Petersen criteria (Petersen, 2004). Finally, subjects with AD dementia met NIA-AA criteria and the diagnostic guidelines of the National Institute of Neurological and Communicative Disorders and Stroke—AD and Related Disorders Association (McKhann et al., 2011) for AD dementia and probable AD (McKhann et al., 1984), respectively.

Based on the NIA-AA research framework guidelines (Jack et al., 2018), each ADNI participant was assigned to a group defined by their respective biomarker profile according to the ATN classification system, irrespective of clinical status as suggested before (Baldacci et al., 2017). Only CN individuals with an A–T–N– profile were considered as healthy controls to exclude preclinical/prodromal AD cases from this group; in addition, patients with MCI with an A–T–N– profile who had reverted to CDR 0 at their last available ADNI follow-up visit were also considered healthy controls for the purposes of the present study, resulting in a final set of 79 controls. To study the effects of fibrillar tau pathology and neuronal injury separately in individuals along the AD continuum, the following groups were defined (irrespective of clinical status): A+T–N– ( $N = 54$ ), A+T+N– ( $N = 64$ ), A+T+N+ ( $N = 129$ ). Furthermore, individuals with suspected non-AD pathology (SNAP) were defined as A–T+N– ( $N = 32$ ) and A–T+N+ ( $N = 20$ ). All other biomarker profiles were not considered for the present study to exclude individuals with non-AD (co)pathologies. The final groups are presented in Table 1.

Included subjects had available structural MRI scans; PET scans to measure glucose metabolisms (F18-fluorodeoxyglucose [FDG]) and fibrillar A $\beta$  load (F18-florbetapir or C11-PiB; note, PiB PET and florbetapir PET yield comparable A $\beta$  binding patterns, using different A $\beta$  imaging tracer compounds (Jagust et al., 2009; Landau et al., 2013); CSF proteins (A $\beta$ 1–42, tTau, and pTau181); and apolipoprotein E (APOE)  $\epsilon$ 4 allele carrier status (dichotomized into carriers vs. noncarriers). In addition included were validated summary metrics for the memory (ADNI-mem; derived from: Rey Auditory Verbal Learning test, AD Assessment Scale—cognitive subscale, Mini-Mental-State Examination, and Wechsler Memory Test—logical memory I) (Crane et al., 2012) and executive cognitive domains (ADNI-ef; derived from the Wechsler Adult Intelligence Scale—Revised Digit Symbol Substitution and Digit Span backwards, Trail Making Test parts A and B, animal and vegetable Category Fluency and Clock Drawing Test) (Gibbons et al., 2012). Summary cognitive scores were chosen over individual cognitive tests to use more comprehensive and robust measures of domain-specific cognitive performance. ADNI was reviewed and approved by all

**Table 1**  
Study groups based on the ATN classification system

ATN profile (diagnosis)	Study group	N
<b>A-T-N- (CN)<sup>a</sup></b>	<b>Healthy controls</b>	<b>79</b>
<b>A+T-N- (CN, MCI, AD)</b>	<b>AD continuum</b>	<b>54</b>
<b>A+T+N- (CN, MCI, AD)</b>		<b>64</b>
<b>A+T+N+ (CN, MCI, AD)</b>		<b>129</b>
<b>A-T+N- (CN, MCI, AD)</b>	<b>SNAP</b>	<b>32</b>
<b>A-T+N+ (CN, MCI, AD)</b>		<b>20</b>
A-T-N+ (AD)	Non-AD change	1
A+T- N+ (AD)	Concomitant non-AD change	1
A-T-N- (MCI, AD)	Normal AD biomarkers	98

Bolded fields indicate ADNI participants classified as either healthy controls, patients along the Alzheimer's continuum or patients with SNAP, who were included in the study; uncolored fields indicate ADNI participants who were excluded from the study because of non-Alzheimer's changes or normal biomarker results despite a diagnosis of MCI or dementia.

Key: CN, cognitively normal; MCI, mild cognitive impairment; AD, Alzheimer's disease (dementia); SNAP, suspected non-AD pathology; ATN, amyloid/tau/neurodegeneration.

<sup>a</sup> Includes MCI individuals classified as CDR = 0 at their last available ADNI visit (N = 11).

host study site review boards, and participants completed informed consent after receiving a comprehensive description of ADNI.

## 2.2. Established biomarkers

A detailed description of biomarker acquisition and performance measures in ADNI can be obtained by registered users at <http://adni.loni.usc.edu/>, with image and CSF collection protocols available elsewhere (Jack et al., 2008; Jagust et al., 2009; Landau et al., 2010, 2012). In brief, TaqMan quantitative polymerase chain reaction assays were used for genotyping *APOE* nucleotides 334 TC and 472 CT with an ABI 7900 real-time thermocycler (Applied Biosystems, Foster City, CA) using DNA freshly prepared from whole blood samples (Bonner-Jackson et al., 2012). Mean FDG count was obtained per subject based on a composite region of interest in an AD typical hypometabolic pattern (Jagust et al., 2009; Landau et al., 2010). For A $\beta$  PET analysis, standardized update value ratios (SUVRs) were calculated with a standardized cortical anatomical automatic labeling volume-of-interest template placed on spatially normalized image volumes using a whole-cerebellum reference region, as previously described (Barthel et al., 2011). Composite SUVRs were calculated as the unweighted mean of the left and right lateral temporal, frontal, posterior cingulate/precuneus, and parietal cortices. The FreeSurfer software (<http://surfer.nmr.mgh.harvard.edu>) was used to extract MRI (1.5 T)–measured hippocampal volume where an atlas-based approach was implemented and has been validated for use in subjects with a great deal of morphologic variability. Uncorrected hippocampal volume for head size was used as a previous study showed that the association between hippocampal volumes and cognition was not altered by intracranial volume normalization (Voevodskaya et al., 2014). Routine peptide CSF measures were generated from aliquot samples collected at the same time (Kim et al., 2011) using commercially available enzyme-linked immunosorbent assays (ELISAs). Validated cutoffs were applied to a differential between normal and pathological findings for CSF pTau181 and tTau (Jagust et al., 2009; Shaw et al., 2009; Steenland et al., 2014), CSF A $\beta$  (Landau et al., 2010, 2013; Shaw et al., 2009; Steenland et al., 2014), FDG PET (Jagust et al., 2009; Landau et al., 2010, 2012), MRI hippocampal volume (Jagust et al., 2009; Landau et al., 2010, 2012, 2013; Shaw et al., 2009; Steenland et al., 2014), and A $\beta$  PET (Jagust et al., 2009; Landau et al., 2010, 2012, 2013; Shaw et al., 2009; Steenland et al.,

2014). Neurofilament light chain (NF-L) was measured in CSF and plasma, using the same antibodies in a commercially available sandwich ELISA and transferred to a SIMOA assay, respectively (Mattsson et al., 2017).

## 2.3. sTREM2 measurements

CSF sTREM2 concentrations were measured in ADNI using two different validated approaches in parallel at two different laboratories: (1) at German Center for Neurodegenerative Disorders Munich an ELISA using the Mesoscale Discovery (MSD) electrochemiluminescence platform was used (Kleinberger et al., 2014; Suarez-Calvet et al., 2016a,b); the assay consists of a biotinylated polyclonal goat IgG anti-human TREM2 antibody as capture antibody, which is raised against amino acids 19–174 of human TREM2; a monoclonal mouse IgG anti-human TREM2 antibody as a detection antibody, which is raised against amino acids 1–160 of human TREM2; and a SULFO-TAG–labeled goat polyclonal IgG anti-mouse secondary antibody. Recombinant human TREM2 protein, corresponding to the extracellular domain of human TREM2 (amino acids 1–174) is used as a standard. The electrochemical signal is measured using the SECTOR Imager 2400 (MSD). All measurements are performed in duplicate and the average is subsequently used for the statistical analyses. (2) At Washington University, Department of Neurology, sTREM2 levels were measured using ELISA method (Piccio et al., 2008, 2016), which uses an anti-human TREM2 monoclonal antibody (clone 20G2) as capture antibody, a biotinylated mouse anti-human TREM-2 mAb (clone 29E3) as detection antibody and recombinant human sTREM2 (Sino Biological Inc) to generate the standard curve. Again, all measurements are performed in duplicate and the average is subsequently used for the statistical analyses. More information about the two different sTREM2 assays, including quality assurance measures, is available on the ADNI website (<http://adni.loni.usc.edu/>).

## 2.4. Statistical analysis

Statistical analysis was performed in R (Version 3.5.1, The R Foundation for Statistical Computing) and IBM SPSS Statistics (Version 20, IBM, New York, USA). Statistical significance level for all tests was  $\alpha = 0.05$ . Analysis of group differences in relation to demographic data, fluid biomarkers, neuroimaging, and cognitive test results was performed with Kruskal-Wallis test or  $\chi^2$  test, as appropriate, with post hoc pairwise comparisons wherever relevant. Differences in sTREM2 concentration between the ATN groups were tested with one-way analysis of variance (ANOVA). sTREM2 was not normally distributed, therefore a cube root transformation was performed before subsequent analysis. Associations between CSF sTREM2 and other fluid biomarkers, imaging, and cognitive test data at the baseline were analyzed using linear regression models corrected for age, sex, educational level, and *APOE* genotype. Longitudinal associations between sTREM2 concentrations at the baseline, fluid biomarkers, imaging, and cognitive test data were assessed using linear mixed-effects model (LME), in which sTREM2 baseline CSF concentration was dichotomized into high versus low by median split method. The LME was calculated with autoregressive covariance matrices, random intercept, and slopes for time and sTREM2 concentration as fixed factor. The interaction between sTREM2 concentration and time (baseline, month 12, month 24, month 36, and month 48) and the fixed effects of time and group (sTREM2 baseline high vs. low) were tested for each ATN group and the entire study cohort. T-tests using Satterthwaite's method were performed to reveal significance for the fixed effects. Changes in sTREM2

concentration over the course of the disease (i.e., between baseline and month 24) where assessed using a repeated ANOVA.

### 3. Results

Characteristics of the study population are presented in Table 2. APOE genotype, ADNI\_mem and ADNI\_ef, CSF sTREM2, A $\beta$ 1–42, tTau and pTau181, and CSF/plasma NF-L differed between the ATN groups at the baseline. CSF sTREM2 concentrations measured using the two different technologies were highly correlated ( $\rho = 0.83$ ,  $p < 0.001$ ); therefore, only the MSD measurements were used for all subsequent statistical analyses because of the higher sensitivity of the electrochemiluminescence platform compared with standard ELISA technology.

#### 3.1. Cross-sectional associations between CSF sTREM2, other biomarkers, and cognition

A multiple linear regression analysis at the baseline revealed positive associations between CSF concentrations of sTREM2 and tTau ( $\beta = 0.06$ ,  $p < 0.001$ ), pTau181 ( $\beta = 0.24$ ,  $p < 0.001$ ), and NF-L ( $\beta = 0.21$ ,  $p = 0.03$ ). No significant associations were found for CSF A $\beta$ 42 ( $\beta = 0.03$ ,  $p = 0.61$ ) and plasma NF-L ( $\beta = -0.12$ ,  $p = 0.21$ ). FDG-PET ( $\beta = -0.06$ ,  $p = 0.31$ ) and MRI total hippocampal volume ( $\beta = -0.06$ ,  $p = 0.42$ ) showed no significant associations with sTREM2 concentration. There was an association on trend level between baseline CSF sTREM2 and ADNI\_mem ( $\beta = -0.1$ ,  $p = 0.08$ )

and no association with ADNI\_ef scores ( $\beta = -0.02$ ,  $p = 0.71$ ). Correlations are shown in Fig. 1.

#### 3.2. CSF sTREM2 concentration differences between ATN groups

Mean sTREM2 concentrations per group are shown in Table 2 and Fig. 2. tTau-positive (A+T+N+) participants showed significantly higher concentrations of sTREM2 compared with healthy controls (A-T-N-,  $p < 0.01$ ) as well as other tTau-negative stages of AD (A+T-N-,  $p < 0.001$ ; A+T-N-,  $p < 0.01$ ). This strong dependency of sTREM2 on tTau was also present in the SNAP group (suspected non-AD pathology, i.e., elevated pTau/tTau but normal A $\beta$ ); A-T+N- showed significantly lower sTREM2 concentrations compared with A-T+N+ ( $p = 0.02$ ).

#### 3.3. Longitudinal associations between CSF sTREM2, cognitive performance, and neuroimaging markers

Longitudinal changes in cognitive performance (ADNI\_mem and ADNI\_ef) and imaging outcomes (FDG-PET composite SUVR, MRI hippocampal volume) were analyzed in relation to the baseline sTREM2 concentrations. The LME analysis showed no time by sTREM2 group interaction (low vs. high) for the entire study cohort as well as for the ATN subgroups individually. With advancing disease stage, a more pronounced decline in all tested variables was observed. There was no significant difference in ADNI\_mem, ADNI\_ef, FDG SUVR, or MRI hippocampal volume between the sTREM2 groups. Estimates of the fixed effects and significances for

**Table 2**  
Characteristics of the study population


Variable	A-T-(N-) (CN) <sup>c</sup> (N=79)	A+T-N- (CN, MCI, AD) (N = 54)	A+T+N- (CN, MCI, AD) (N = 64)	A+T+N+ (CN, MCI, AD) (N = 129)	A-T+N- (CN, MCI, AD) (N=32)	A-T+N+ (CN, MCI, AD) (N=20)	p Value
Age, years, mean (SD)	72.4 (6.3)	74.2 (6.6)	74.9 (5.8)	73.8 (7.8)	72.3 (7.4)	76.1 (7.5)	0.105 <sup>a</sup>
Female, N (%)	43 (49.8)	33 (47.6)	33 (47.3)	48 (50.2)	31 (47.1)	55 (51.0)	0.120 <sup>b</sup>
Education, mean (SD) years	16.0 (2.9)	15.1 (2.9)	16.3 (2.9)	15.8 (2.7)	15.8 (2.8)	15.9 (3.2)	0.313 <sup>a</sup>
APOE $\epsilon$ 4 carriers, N (%)	16 (37)	56 (50.2)	67 (47.3)	71 (45.4)	16 (36.9)	25 (44.4)	<0.001 <sup>b</sup>
ADNI_ef, mean (SD)	0.78 (0.66)	0.11 (0.83)	-0.67 (0.95)	-0.15 (0.90)	0.58 (0.83)	0.34 (0.66)	<0.001 <sup>a</sup>
ADNI_mem, mean (SD)	0.92 (0.55)	0.26 (0.65)	0.06 (0.78)	-0.19 (0.72)	0.72 (0.64)	0.64 (0.69)	<0.001 <sup>a</sup>
NF-L plasma <sup>c</sup> , mean (SD), pg/mL	27.38 (10.65)	46.75 (39.19)	46.94 (27.34)	39.46 (12.96)	23.43 (6.96)	33.92 (17.44)	0.01 <sup>a</sup>
NF-L CSF <sup>c</sup> , mean (SD), pg/mL	995.56 (258.74)	1261.22 (635.52)	1247.16 (483.92)	1629.62 (513.34)	1347.34 (394.49)	1320.60 (204.12)	<0.001 <sup>a</sup>
CSF sTREM2 mean (SD), pg/mL	2572.10 (1596.09)	3110.76 (1425.49)	3617.73 (1651.78)	4577.71 (2151.30)	3716.45 (2031.35)	5317.08 (2619.21)	<0.001 <sup>a</sup>
CSF A 42, mean (SD), ng/L	261.10 (39.79)	144.83 (29.08)	139.57 (32.64)	140.26 (27.02)	287.21 (55.43)	255.04 (45.87)	<0.001 <sup>a</sup>
CSF tTau, mean, (SD), ng/L	53.43 (15.90)	59.62 (14.71)	74.71 (14.49)	158.87 (60.27)	68.65 (16.00)	122.79 (33.20)	<0.001 <sup>a</sup>
CSF pTau181, mean, (SD), ng/L	16.00 (3.44)	18.09 (3.28)	34.51 (10.36)	42.48 (16.69)	28.46 (4.20)	31.77 (9.33)	<0.001 <sup>a</sup>

Key: CN, cognitively normal; MCI, mild cognitive impairment; AD, Alzheimer's disease (dementia); SNAP, suspected non-AD pathology; APOE, apolipoprotein E, ADNI, Alzheimer's Disease Neuroimaging Initiative; ADNI\_ef, executive domain summary score; ADNI\_mem, memory domain summary score; CSF, cerebrospinal fluid; NF-L, neurofilament light chain; sTREM2, soluble Triggering receptor expressed on myeloid cells 2; A, amyloid; tTau, total tau; pTau, phosphorylated tau; ATN, amyloid/tau/neurodegeneration.

<sup>a</sup> Kruskal Wallis test.

<sup>b</sup>  $\chi^2$  test.

<sup>c</sup> Only ADNI 1 data available.



**Fig. 1.** Associations between CSF sTREM2, other biomarkers, and cognitive performance in the entire study cohort. Abbreviations: ADNI, Alzheimer’s Disease Neuroimaging Initiative; ADNI\_ef, executive domain summary score; ADNI\_mem, memory domain summary score; CSF, cerebrospinal fluid; NF-L, neurofilament light chain; sTREM2, soluble Triggering receptor expressed on myeloid cells 2; A, amyloid; tTau, total tau; pTau, phosphorylated tau; ATN, amyloid/tau/neurodegeneration.

the factors time and group as well as the time by group interactions are shown in Table 3.


**3.4. Changes in sTREM2 concentration over the course of the disease**

Changes of sTREM2 concentrations measured with the MSD assay over time were analyzed using a repeated measure ANOVA, comparing baseline versus 24-month measurements. No significant time by ATN group interaction was found ( $p = 0.44$ ), but a

significant increase in sTREM2 concentration after 48 months was demonstrated in the entire cohort ( $p < 0.001$ ) (Fig. 3). Pairwise comparisons revealed significant differences between A+T+N+ and A-T-N- ( $p < 0.01$ ), A+T-N- ( $p < 0.01$ ), and A+T+N- ( $p < 0.01$ ).

**4. Discussion**

An improved mechanistic understanding of biomarker changes related to different types of pathology is a key prerequisite of improving the diagnosis, prevention, and clinical management of



**Fig. 2.** CSF sTREM2 concentration differences between the ATN subgroups. \*  $p = 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ; \*\*\*\*  $p < 0.0001$ . Abbreviations: A/T/N, amyloid/tau/neurodegeneration; CSF, cerebrospinal fluid; sTREM2, soluble Triggering receptor expressed on myeloid cells 2.

**Table 3**  
Results of the linear mixed effects model analysis for ADNI\_mem, ADNI\_ef, FDG PET SUVR and hippocampal volume

Variables	All participants β, (p)	A–T–N– β, (p)	A+T–N– β, (p)	A+T+N– β, (p)	A+T+N+ β, (p)	A–T+N– β, (p)	A–T+N+ β, (p)
ADNI_mem							
Time	–0.111 (<0.001)	0.026 (0.17)	–0.066 (0.02)	0.030 (<0.001)	0.024 (<0.001)	–0.029 (0.42)	–0.099 (0.06)
Group (sTREM2)	–0.151 (0.08)	–0.174 (0.08)	0.353 (0.07)	0.099 (0.68)	–0.088 (0.52)	0.275 (0.28)	–0.017 (0.96)
Interaction (time × group)	0.013 (0.54)	0.028 (0.29)	0.078 (0.16)	–0.004 (0.94)	0.030 (0.40)	0.040 (0.54)	0.095 (0.17)
ADNI_ef							
Time	–0.109 (<0.001)	0.003 (0.90)	–0.115 (0.01)	–0.168 (<0.001)	–0.212 (<0.001)	0.016 (0.70)	–0.038 (0.54)
Group (sTREM2)	–0.049 (0.63)	0.080 (0.66)	–0.051 (0.85)	0.163 (0.55)	–0.142 (0.41)	0.362 (0.30)	–0.067 (0.85)
Interaction (time × group)	–0.012 (0.65)	–0.045 (0.24)	0.057 (0.50)	0.006 (0.93)	0.014 (0.77)	0.063 (0.40)	0.037 (0.66)
FDG PET comp. SUVR							
Time	–0.020 (<0.001)	–0.005 (0.28)	–0.014 (0.01)	–0.027 (<0.001)	–0.040 (<0.001)	NA	–0.014 (<0.001)
Group (sTREM2)	0.002 (0.91)	–0.036 (0.26)	0.003 (0.96)	0.056 (0.16)	0.015 (0.56)	NA	–0.015 (0.91)
Interaction (time × group)	–0.001 (0.88)	0.001 (0.83)	0.007 (0.46)	–0.007 (0.58)	0.008 (0.32)	NA	–0.0002 (0.88)
Hippocampal volume							
Time	–393.33 (<0.001)	–465.04 (<0.001)	–310.04 (<0.001)	–281.79 (<0.001)	–474.31 (<0.001)	–332.51 (0.001)	–393.33 (<0.001)
Group (sTREM2)	–61.99 (0.80)	–551.85 (0.36)	–13.95 (0.98)	773.10 (0.12)	–597.71 (0.11)	1931.71 (0.08)	–61.99 (0.80)
Interaction (time × group)	16.42 (0.72)	209.47 (0.07)	–99.42 (0.48)	128.66 (0.27)	105.67 (0.12)	–362.72 (0.07)	16.42 (0.72)

Key: ADNI, Alzheimer's Disease Neuroimaging Initiative; ADNI\_ef, executive domain summary score; ADNI\_mem, memory domain summary score; ATN, amyloid/tau/neurodegeneration; FDG, F18-fluorodeoxyglucose; PET, positron-emission-tomography; sTREM2, soluble Triggering receptor expressed on myeloid cells 2; SUVR, standardized uptake value ratio.


Estimates of the fixed effects (β values) are shown for the fixed factors time and group and time by group interaction for the whole study population and the ATN subgroups (p values obtained from t-tests using Satterthwaite's method).

AD. Neuroinflammation has become a key target for biomarker research, and TREM2 has recently been identified as an interesting new biomarker candidate, reflecting microglia activation and innate immune response in different neurodegenerative diseases including AD. Previous studies indicate that sTREM2 concentrations in CSF are increased in the early symptomatic stages of AD (Suarez-Calvet et al., 2016b), but the association of CSF sTREM2 with other more established fluid and imaging biomarkers is not well understood, in particular, when it comes to biomarker changes and associations over time.

In a bid to determine how CSF sTREM2 concentrations are related to the core pathological changes along the AD continuum, we used a subset of the ADNI cohort with available CSF and other relevant biomarker results. We decided to apply a biomarker-based staging system based on the recently published NIA-AA research

framework, which is a strength of our approach that allowed us to explore associations in relation to the underlying presence or absence of key aspects of AD pathophysiology (i.e., Aβ, pTau, and Tau) rather than the clinical phenotype.

The main findings of our study are that (1) different established immunologic methods result in comparable CSF sTREM2 measurements; (2) CSF sTREM2 concentrations are correlated with CSF markers of fibrillar tau (pTau181) and neuronal injury (tTau and NF-L) but not amyloidosis (CSF Aβ42); (3) tTau-positive individuals have higher CSF concentrations of sTREM2 compared with both healthy controls and tTau-negative patients along the AD continuum; (4) CSF sTREM2 is not associated with cognitive and other biomarker changes over time; and (5) CSF sTREM2 concentrations increase over time in tTau-positive patients with AD compared with tTau-negative patients with AD pathophysiology.



**Fig. 3.** Changes in CSF sTREM2 concentration in the whole study cohort of the AD spectrum. \*\*\*\*  $p < 0.0001$ . Abbreviations: CSF, cerebrospinal fluid; sTREM2, soluble Triggering receptor expressed on myeloid cells 2.

The findings of the present study are in line with previous results indicating that higher sTREM2 concentrations in CSF are linked to neuronal injury (i.e., CSF tTau and NF-L), even in the absence of A $\beta$  pathology as indicated by differences between healthy controls and SNAP individuals (Suarez-Calvet et al., 2016b). Our study extends previous evidence by showing that fibrillar tau pathology in the absence of neurodegeneration is not associated with increased sTREM2 CSF levels. The findings also suggest that tau and A $\beta$  may have opposite associations with sTREM2 in CSF, with A $\beta$  being associated with lower sTREM2 concentrations in the absence of tau pathology (nonsignificant finding, but conclusion supported by Fig. 1). These findings may explain why some previous studies report conflicting results in relation to sTREM2 changes when individuals are classified according to their clinical status rather than their AD biomarker profile, which results in biologically heterogeneous cohorts (Heslegrave et al., 2016; Piccio et al., 2016; Suarez-Calvet et al., 2016b).

The association between TREM2 and tTau seems to follow a consistent pattern, both for genetic associations with the *TREM2* gene and for the soluble form in CSF. For example, carriers of the *TREM2* rs75932628 risk allele showed increased levels of CSF tTau but not A $\beta$ 42. These consistent findings suggest that sTREM2 increases if neuronal injury occurs, even if A $\beta$  pathology is absent. Increased sTREM2 seems to be a consequence rather than a cause of neurodegeneration, in line with reports that the TREM2 receptor mediates the phagocytosis of apoptotic neurons by microglia (Wang et al., 2015). At the same time, sTREM2 as a biomarker of AD is likely to offer complementary, rather than redundant, information to tTau and pTau, which are passively released to CSF from decaying neurons, whereas the production and shedding of TREM2 by microglia is a physiological process, making sTREM2 a biomarker candidate of microglia activation in the context of AD. The association between microglial activation and increased sTREM2 concentrations is in line with elevated TREM2 expression (Matarin et al., 2015) and higher translocator protein tracer uptake in PET studies (Brendel et al., 2017). There are conflicting hypotheses if microglial activation during early AD stages is neuroprotective, detrimental, or merely reactive to advancing A $\beta$  pathology. The increase of sTREM2 during physiological aging and the association between misfolded mutant TREM2 and impaired microglial phagocytosis may point to a protective effect, at least as neurodegeneration starts to develop (Kleinberger et al., 2014; Piccio et al., 2016). However, distinct disease-associated TREM2 mutations may have opposite mechanisms on the cellular level because, for example, R47H mutations associated with AD do not show decreased TREM2 shedding (Kleinberger et al., 2014).

A few limitations of the study must be acknowledged. First, standardization of biomarker cutoffs is currently limited and results often vary among laboratories; however, current cutoffs have been used in numerous ADNI studies, and appear to show reasonable validity for the purposes of this article (Alexopoulos et al., 2014; Jagust et al., 2009; Landau et al., 2010, 2012, 2013; Shaw et al., 2009). Second, the ADNI cohort is mainly white, middle class, educated, and without any major comorbidity; thus, it would be important to repeat such a study with a larger and more widely represented demographic which also considers relevant comorbid conditions such as cerebrovascular disease. Third, our analyses only consider biomarker and clinical changes over the period of 48 months, and longer follow-up periods may reveal additional informative changes and associations. Fourth, there was no histopathological verification of the clinical diagnoses, but the ADNI cohort is on purpose enriched with probable predementia AD cases, evidenced by the first autopsy studies (Toledo et al., 2013). Finally, there are some missing data, especially in later visit time points as

study participants drop off, which is a typical pattern observed in prospective clinical research.

To conclude, our work provides intriguing evidence in support of sTREM2 in CSF as a marker of neuroinflammation across the spectrum of early clinical AD; sTREM2 is linked statistically and biologically to neuronal injury and may therefore offer complementary information relevant for diagnostic purposes and novel treatment approaches targeting the immune system. Moving forward, future studies should use biomarker information to further categorize clinical AD stages (e.g., MCI) and to explore the biological mechanisms underlying the dynamic sTREM2 changes.

## Disclosure statement

The authors have no actual or potential conflicts of interest.

## Acknowledgements

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amofix Life Sciences Ltd; AstraZeneca; Bayer HealthCare; BioClinica, Inc; Biogen Idec Inc; Bristol-Myers Squibb Company; Eisai Inc; Elan Pharmaceuticals Inc; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc; Merck & Co, Inc; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Servier; Synarc Inc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org)). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514. The sponsors did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the article.

## References

- Alexopoulos, P., Grimmer, T., Perneczky, R., Kurz, A., Kriett, L., Klupp, E., Förster, S., Yakushev, I., Haller, B., Gray, K., Laskaris, N., Drzezga, A., Fellgiebel, A., 2014. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. *Alzheimer's Dement.* 10, 684–689.
- Alosco, M.L., Tripodis, Y., Fritts, N.G., Heslegrave, A., Baugh, C.M., Conneely, S., Mariani, M., Martin, B.M., Frank, S., Mez, J., Stein, T.D., Cantu, R.C., McKee, A.C., Shaw, L.M., Trojanowski, J.Q., Blennow, K., Zetterberg, H., Stern, R.A., 2018. Cerebrospinal fluid tau, Abeta, and sTREM2 in Former National Football League Players: modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. *Alzheimer's Dement.* 14, 1159–1170.
- Baldacci, F., Toschi, N., Lista, S., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S., Cavedo, E., Dos Santos, A.M., Epelbaum, S., Lamari, F., Dubois, B., Floris, R., Garaci, F., Bonuccelli, U., Hampel, H., 2017. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. *Alzheimer's Dement.* 13, 993–1003.
- Barthel, H., Gertz, H.J., Dresel, S., Peters, O., Bartenstein, P., Buerger, K., Hiemeyer, F., Wittmer-Rump, S.M., Seibyl, J., Reiningger, C., Sabri, O., Florbetaben Study, G., 2011. Cerebral amyloid-beta PET with florbetaben (18F) in patients with

- Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. *Lancet Neurol.* 10, 424–435.
- Bonner-Jackson, A., Okonkwo, O., Tremont, G., Alzheimer's Disease Neuroimaging, I., 2012. Apolipoprotein E epsilon2 and functional decline in amnesic mild cognitive impairment and Alzheimer disease. *Am. J. Geriatr. Psychiatr.* 20, 584–593.
- Borrioni, B., Ferrari, F., Galimberti, D., Nacmias, B., Barone, C., Bagnoli, S., Fenoglio, C., Piaceri, I., Archetti, S., Bonvicini, C., Gennarelli, M., Turla, M., Scarpini, E., Sorbi, S., Padovani, A., 2014. Heterozygous TREM2 mutations in frontotemporal dementia. *Neurobiol. Aging* 35, 934.e7–934.e10.
- Brendel, M., Kleinberger, G., Probst, F., Jaworska, A., Overhoff, F., Blume, T., Albert, N.L., Carlsen, J., Lindner, S., Gildehaus, F.J., Ozmen, L., Suarez-Calvet, M., Bartenstein, P., Baumann, K., Ewers, M., Herms, J., Haass, C., Rominger, A., 2017. Increase of TREM2 during aging of an Alzheimer's disease mouse model is paralleled by microglial activation and amyloidosis. *Front. Aging Neurosci.* 9, 8.
- Cady, J., Koval, E.D., Benitez, B.A., Zaidman, C., Jockel-Balsarotti, J., Allred, P., Baloh, R.H., Ravits, J., Simpson, E., Appel, S.H., Pestronk, A., Goate, A.M., Miller, T.M., Cruchaga, C., Harms, M.B., 2014. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. *JAMA Neurol.* 71, 449–453.
- Cherry, J.D., Tripodis, Y., Alvarez, V.E., Huber, B., Kiernan, P.T., Daneshvar, D.H., Mez, J., Montenegro, P.H., Solomon, T.M., Alosco, M.L., Stern, R.A., McKee, A.C., Stein, T.D., 2016. Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. *Acta Neuropathol. Commun.* 4, 112.
- Crane, P.K., Carle, A., Gibbons, L.E., Insel, P., Mackin, R.S., Gross, A., Jones, R.N., Mukherjee, S., Curtis, S.M., Harvey, D., Weiner, M., Mungas, D., Alzheimer's Disease Neuroimaging, I., 2012. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Brain Imaging Behav.* 6, 502–516.
- Cuyvers, E., Bettens, K., Philtjens, S., Van Langenhove, T., Gijssels, I., van der Zee, J., Engelborghs, S., Vandenbulcke, M., Van Dongen, J., Geerts, N., Maes, G., Mattheijssens, M., Peeters, K., Cras, P., Vandenberghe, R., De Deyn, P.P., Van Broeckhoven, C., Cruts, M., Sleegers, K., Consortium, B., 2014. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. *Neurobiol. Aging* 35, 726.e711–726.e729.
- Giaccone, G., Arzberger, T., Alafuzoff, I., Al-Sarraj, S., Budka, H., Duyckaerts, C., Falkai, P., Ferrer, I., Ironside, J.W., Kovacs, G.G., Meyronet, D., Parchi, P., Patzsch, E., Revesz, T., Riederer, P., Roemmler, A., Schmitt, A., Winblad, B., Katsirchak, H., 2011. New lexicon and criteria for the diagnosis of Alzheimer's disease. *Lancet Neurol.* 10, 298–299 author reply 300–301.
- Gibbons, L.E., Carle, A.C., Mackin, R.S., Harvey, D., Mukherjee, S., Insel, P., Curtis, S.M., Mungas, D., Crane, P.K., Alzheimer's Disease Neuroimaging, I., 2012. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. *Brain Imaging Behav.* 6, 517–527.
- Gispert, J.D., Monte, G.C., Suarez-Calvet, M., Falcon, C., Tucholka, A., Rojas, S., Rami, L., Sanchez-Valle, R., Llado, A., Kleinberger, G., Haass, C., Molinuevo, J.L., 2017. The APOE epsilon4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. *Alzheimers Dement. (Amst.)* 6, 50–59.
- Gispert, J.D., Suarez-Calvet, M., Monte, G.C., Tucholka, A., Falcon, C., Rojas, S., Rami, L., Sanchez-Valle, R., Llado, A., Kleinberger, G., Haass, C., Molinuevo, J.L., 2016. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. *Alzheimers Dement.* 12, 1259–1272.
- Guerreiro, R.J., Lohmann, E., Bras, J.M., Gibbs, J.R., Rohrer, J.D., Gurunlian, N., Dursun, B., Bilgic, B., Hanagasi, H., Gurvit, H., Emre, M., Singleton, A., Hardy, J., 2013a. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. *JAMA Neurol.* 70, 78–84.
- Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogava, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J.S., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J.C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George-Hyslop, P., Singleton, A., Hardy, J., Alzheimer Genetic Analysis, G., 2013b. TREM2 variants in Alzheimer's disease. *N. Engl. J. Med.* 368, 117–127.
- Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Ohrfelt, A., Blennow, K., Hardy, J., Schott, J., Mills, K., Zetterberg, H., 2016. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. *Mol. Neurodegener.* 11, 3.
- Jack Jr., C.R., Albert, M.S., Knopman, D.S., McKhann, G.M., Sperling, R.A., Carrillo, M.C., Thies, B., Phelps, C.H., 2011. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 7, 257–262.
- Jack Jr., C.R., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., Holtzman, D.M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J.L., Montine, T., Phelps, C., Rankin, K.P., Rowe, C.C., Scheltens, P., Siemers, E., Snyder, H.M., Sperling, R., Contributors, 2018. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 14, 535–562.
- Jack Jr., C.R., Bernstein, M.A., Fox, N.C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P.J., J. L.W., Ward, C., Dale, A.M., Felmlee, J.P., Gunter, J.L., Hill, D.L., Killiany, R., Schuff, N., Fox-Bosetti, S., Lin, C., Studholme, C., DeCarli, C.S., Krueger, G., Ward, H.A., Metzger, G.J., Scott, K.T., Malloy, R., Blezek, D., Levy, J., Debbins, J.P., Fleisher, A.S., Albert, M., Green, R., Bartzokis, G., Glover, G., Mugler, J., Weiner, M.W., 2008. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. *J. Magn. Reson. Imaging* 27, 685–691.
- Jagust, W., Landau, S.M., Shaw, L., Trojanowski, J., Koeppe, R., Reiman, E., Foster, N., Petersen, R.C., Weiner, M., Price, J., Mathis, C., 2009. Relationships between biomarkers in aging and dementia. *Neurology* 73, 1193–1199.
- Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A.L., Lah, J.J., Rujescu, D., Hampel, H., Giegling, I., Andreassen, O.A., Engedal, K., Ulstein, I., Djurovic, S., Ibrahim-Verbaas, C., Hofman, A., Ikram, M.A., van Duijn, C.M., Thorsteinsdottir, U., Kong, A., Stefansson, K., 2013. Variant of TREM2 associated with the risk of Alzheimer's disease. *N. Engl. J. Med.* 368, 107–116.
- Kim, S., Swaminathan, S., Shen, L., Risacher, S.L., Nho, K., Foroud, T., Shaw, L.M., Trojanowski, J.Q., Potkin, S.G., Huentelman, M.J., Craig, D.W., DeChairo, B.M., Aisen, P.S., Petersen, R.C., Weiner, M.W., Saykin, A.J., Alzheimer's Disease Neuroimaging, I., 2011. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. *Neurology* 76, 69–79.
- Kleinberger, G., Brendel, M., Mraacso, E., Wefers, B., Groeneweg, L., Xiang, X., Focke, C., Deuling, M., Suarez-Calvet, M., Mazaheri, F., Parhizkar, S., Pettkus, N., Wurs, W., Feederle, R., Bartenstein, P., Mueggler, T., Arzberger, T., Knuesel, I., Rominger, A., Haass, C., 2017. The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion and glucose metabolism. *EMBO J.* 36, 1837–1853.
- Kleinberger, G., Yamanishi, Y., Suarez-Calvet, M., Czirz, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Weninger-Weinzierl, A., Mazaheri, F., Tahirovic, S., Lleo, A., Alcolea, D., Fortea, J., Willem, M., Lammich, S., Molinuevo, J.L., Sanchez-Valle, R., Antonell, A., Ramirez, A., Heneka, M.T., Sleegers, K., van der Zee, J., Martin, J.J., Engelborghs, S., Demirtas-Tatilde, A., Zetterberg, H., Van Broeckhoven, C., Gurvit, H., Wyss-Coray, T., Hardy, J., Colonna, M., Haass, C., 2014. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. *Sci. Transl. Med.* 6, 243–286.
- Landau, S.M., Harvey, D., Madison, C.M., Reiman, E., Foster, N., Aisen, P.S., Petersen, R.C., Shaw, L., Trojanowski, J., Jack, C.R., Weiner, M., Jagust, W., 2010. Comparing predictors of conversion and decline in mild cognitive impairment. *Neurology* 75, 230–238.
- Landau, S.M., Jagust, W.J., Mintun, M.A., Joshi, A.D., Koeppe, R.A., Petersen, R.C., Aisen, P.S., Weiner, M.W., 2012. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Ann. Neurol.* 72, 578–586.
- Landau, S.M., Lu, M., Joshi, A.D., Pontecorvo, M., Mintun, M.A., Trojanowski, J.Q., Shaw, L.M., Jagust, W.J., 2013. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. *Ann. Neurol.* 74, 826–836.
- Matarin, M., Salih, D.A., Yasvoina, M., Cummings, D.M., Guelfi, S., Liu, W., Nahaboo Solim, M.A., Moens, T.G., Paublete, R.M., Ali, S.S., Perona, M., Desai, R., Smith, K.J., Latcham, J., Fullelylove, M., Richardson, J.C., Hardy, J., Edwards, F.A., 2015. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. *Cell Rep.* 10, 633–644.
- Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., Alzheimer's Disease Neuroimaging, I., 2017. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. *JAMA Neurol.* 74, 557–566.
- McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. *Neurology* 34, 939–944.
- McKhann, G.M., 2011. Changing concepts of Alzheimer disease. *JAMA* 305, 2458–2459.
- McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack Jr., C.R., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H., 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 7, 263–269.
- Petersen, R.C., 2004. Mild cognitive impairment as a diagnostic entity. *J. Intern. Med.* 256, 183–194.
- Piccio, L., Buonsanti, C., Cella, M., Tassi, I., Schmidt, R.E., Fenoglio, C., Rinker 2nd, J., Naismith, R.T., Panina-Bordignon, P., Passini, N., Galimberti, D., Scarpini, E., Colonna, M., Cross, A.H., 2008. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. *Brain* 131 (Pt 11), 3081–3091.
- Piccio, L., Deming, Y., Del-Aguila, J.L., Ghezzi, L., Holtzman, D.M., Fagan, A.M., Fenoglio, C., Galimberti, D., Borrioni, B., Cruchaga, C., 2016. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. *Acta Neuropathol.* 131, 925–933.
- Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W.W., Hatanpaa, K.J., Lomen-Hoerth, C., Kertesz, A., Bigio, E.H., Lipka, C., Josephs, K.A., Knopman, D.S., White 3rd, C.L., Caselli, R., Mackenzie, I.R., Miller, B.L., Boczarzka-Jedynak, M., Opala, G., Krygowska-Wajs, A., Barcikowska, M., Younkin, S.G., Petersen, R.C., Ertekin-Taner, N., Uitti, R.J., Meschia, J.F., Boylan, K.B., Boeve, B.F., Graff-Radford, N.R., Wszolek, Z.K., Dickson, D.W., Rademakers, R., Ross, O.A., 2013. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. *Mol. Neurodegener.* 8, 19.
- Shaw, L., Vanderstichele, H., Knopik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V., Trojanowski, J., 2009. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Ann. Neurol.* 65, 403–413.

- Steenland, K., Zhao, L., Goldstein, F., Cellar, J., Lah, J., 2014. Biomarkers for predicting cognitive decline in those with normal cognition. *J. Alzheimers Dis.* 40, 587–594.
- Suarez-Calvet, M., Araque Caballero, M.A., Kleinberger, G., Bateman, R.J., Fagan, A.M., Morris, J.C., Levin, J., Danek, A., Ewers, M., Haass, C., 2016a. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. *Sci. Transl. Med.* 8, 369ra178.
- Suarez-Calvet, M., Kleinberger, G., Araque Caballero, M.A., Brendel, M., Rominger, A., Alcolea, D., Forste, J., Lleó, A., Blesa, R., Gispert, J.D., Sanchez-Valle, R., Antonell, A., Rami, L., Molinuevo, J.L., Brosseron, F., Truschutz, A., Heneka, M.T., Struyfs, H., Engelborghs, S., Sleegers, K., Van Broeckhoven, C., Zetterberg, H., Nelldgaard, B., Blennow, K., Crispin, A., Ewers, M., Haass, C., 2016b. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. *EMBO Mol. Med.* 8, 466–476.
- Toledo, J.B., Cairns, N.J., Da, X., Chen, K., Carter, D., Fleisher, A., Householder, E., Ayutyanont, N., Roontiva, A., Bauer, R.J., Eisen, P., Shaw, L.M., Davatzikos, C., Weiner, M.W., Reiman, E.M., Morris, J.C., Trojanowski, J.Q., Alzheimer's Disease Neuroimaging, I., 2013. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. *Acta Neuropathol. Commun.* 1, 65.
- Ulland, T.K., Song, W.M., Huang, S.C., Ulrich, J.D., Sergushichev, A., Beatty, W.L., Loboda, A.A., Zhou, Y., Cairns, N.J., Kambal, A., Loggincheva, E., Gilfillan, S., Cella, M., Virgin, H.W., Unanue, E.R., Wang, Y., Artyomov, M.N., Holtzman, D.M., Colonna, M., 2017. TREM2 maintains microglial metabolic fitness in Alzheimer's disease. *Cell* 170, 649–663.e613.
- Voevodskaya, O., Simmons, A., Nordenskjöld, R., Kullberg, J., Ahlstrom, H., Lind, L., Wahlund, L.O., Larsson, E.M., Westman, E., Alzheimer's Disease Neuroimaging, I., 2014. The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease. *Front. Aging Neurosci.* 6, 264.
- Walton, R.L., Soto-Ortolaza, A.I., Murray, M.E., Lorenzo-Betancor, O., Ogaki, K., Heckman, M.G., Rayaprolu, S., Rademakers, R., Ertekin-Taner, N., Uitti, R.J., van Gerpen, J.A., Wszolek, Z.K., Smith, G.E., Kantarci, K., Lowe, V.J., Parisi, J.E., Jones, D.T., Savica, R., Graff-Radford, J., Knopman, D.S., Petersen, R.C., Graff-Radford, N.R., Ferman, T.J., Dickson, D.W., Boeve, B.F., Ross, O.A., Labbe, C., 2016. TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. *Neurol. Genet.* 2, e85.
- Wang, Y., Cella, M., Mallinson, K., Ulrich, J.D., Young, K.L., Robinette, M.L., Gilfillan, S., Krishnan, G.M., Sudhakar, S., Zinselmeyer, B.H., Holtzman, D.M., Cirrito, J.R., Colonna, M., 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. *Cell* 160, 1061–1071.